Govorestat

Govorestat
Clinical data
Other namesAT-007
ATC code
Identifiers
  • 2-[4-Oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]thieno[3,4-d]pyridazin-1-yl]acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC17H10F3N3O3S2
Molar mass425.40 g·mol−1
3D model (JSmol)
  • C1=CC2=C(C=C1C(F)(F)F)N=C(S2)CN3C(=O)C4=CSC=C4C(=N3)CC(=O)O
  • InChI=1S/C17H10F3N3O3S2/c18-17(19,20)8-1-2-13-12(3-8)21-14(28-13)5-23-16(26)10-7-27-6-9(10)11(22-23)4-15(24)25/h1-3,6-7H,4-5H2,(H,24,25)
  • Key:ORQGHAJIWGGFJK-UHFFFAOYSA-N

Govorestat (AT-007) is an aldose reductase inhibitor and experimental drug to treat galactosemia[1] and sorbitol dehydrogenase deficiency.[2]

After a report circulating on the internet accused the developer Applied Therapeutics of cutting corners in its studies of the drug, the FDA put a hold on it in 2020. Applied Therapeutics said that the report was a fraudulent attempt to manipulate its stock price.[3]

References

  1. ^ Bailey, Evan; Wang, Stella; Saltonstall, Laura; Perfetti, Riccardo; Shendelman, Shoshana (March 2022). "OP005: AT-007 significantly reduces toxic galactitol in ACTION-galactosemia kids - the 1st therapeutic interventional clinical trial in children with classic galactosemia". Genetics in Medicine. 24 (3): S336. doi:10.1016/j.gim.2022.01.556. S2CID 247603696.
  2. ^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 5 November 2023.
  3. ^ "Bad to worse for Applied Therapeutics as FDA slaps partial clinical hold on rare drug". Retrieved 4 November 2023.